C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M

C4 Therapeutics, Inc.

CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.
Net loss $27.0M ($0.55 per share) vs $32.0M ($0.65) in Q3 2022; revenue $11.1M (up from $6.8M) from Roche and Biogen collaborations.
Cash, equivalents and marketable securities $246.4M as of Sept 30, 2023; expected runway into H2 2025.
CFT7455 Phase 1 dose escalation completed in monotherapy for R/R MM; combination arm continues; virtual event on Dec 12, 2023.
Kendra Adams appointed CFO in September 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 1, 2023, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-035790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.